AUTO-4 (Autolus)
- Generic Name
- AUTO-4 (Autolus)
Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma
Phase 1
Completed
- Conditions
- Angioimmunoblastic T-cell LymphomaAnaplastic Large Cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedT Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Autolus Limited
- Target Recruit Count
- 20
- Registration Number
- NCT03590574
- Locations
- 🇬🇧
Manchester Royal Infirmary Hospital, Manchester, United Kingdom
🇪🇸Vall d'Hebron Institute of Oncology, Barcelona, Spain
🇬🇧Queen Elizabeth University Hospital, Glasgow, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath